A Dose-block Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Safety, Tolerability, and PK/PD of GX-G3 After Single SC Administration in Healthy Male Subjects

Trial Profile

A Dose-block Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Safety, Tolerability, and PK/PD of GX-G3 After Single SC Administration in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2015

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Adverse reactions
  • Sponsors Genexine
  • Most Recent Events

    • 28 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top